Synopsis
Introduction

49
Human immunodeficiency virus (HIV) is currently an incurable disease which 50 constitutes a serious global health crisis. Oral antiretroviral therapy is the mainstay of 51 current therapy and involves coadminstration of drugs targeting multiple viral targets.
52
Both drug-related adverse reactions and drug resistance have led to the 53 development of newer antiretroviral drugs and drug classes. However, the cost and 54 dosing schedule of treatments are a significant concern in low-and middle-income 55 countires (L&MICs). Several effective antiretroviral drugs are now manufactured as 56 generics and are marketed with significant cost savings to payers (1, 2) . oral bioavailability (around 13%) (4) and TDF was developed to improve this by 63 removing charged regions and increasing lipophilicity. However, the oral 64 bioavailability of TDF was only moderately improved and is estimated at around 25% assessed between days 8, 15 and 35 days of the study (6). Therefore, a mean and 135 standard deviation between these assessment days was calculated and used for 136 comparison with simulated data. The clinical C max (335 ng mL -1 ), T max (2.4 hr) and 137 AUC 0-24hr (3045 ng.hr mL -1 ) were all within 0.5-fold difference of the simulated C max
138
(238 ng mL -1 , 0.41-fold higher), T max (3 hr, 0.2-fold lower) and AUC 0-24hr (3036 ng.hr 139 mL -1 , 0-fold difference). The observed median TFV C 24hr following seven days of 140 once-daily 300 mg oral dosing was 48.3 ng mL -1 , which was within the acceptable 141 range of the median simulated TDF C 24hr of 42.7 ng mL -1 ( Figure 2A 
Absorption of TDF and TFV
335
TDF permeation through a Caco-2 monolayer has been previously investigated and 336 the apparent permeability (P app ) was found to be drug-concentration-dependent (7).
(specifically saturation of ABCB1) when higher TDF concentrations were added to 339 the receiver compartment. Where TDF Papp is the estimated TDF P app value at a specific concentration of TDF;
348
TDF conc is the concentration of TDF.
Using previously established equations, P app was used to generate the rate of drug clearance rate of 0.066 L/hr/kg was derived from a previous population 368 pharmacokinetic study and was included in our model (6). (75, 150, 300, and 600 mg given once daily) with between eight and nine subjects in 377 each group (6). Additionally, the terminal plasma half life of TDF was estimates from 378 simulated concentration plots and compared to half life generated from clinical data.
379
The bioavailability of orally administered TDF is estimated at around 25 % of the total 380 dose (26) and the bioavailability of 300 mg orally administered TDF was determined 
387
To validate the robustness of the model further, simulations were performed as 388 described above but using alternative TDF oral dose sizes (75 mg, 150 mg, 600 mg).
389
Pharmacokinetic parameters (median TFV C max , T max , AUC 0-24hr and C 24hr ) were 390 generated from these simulations and were compared to available clinical 391 pharmacokinetic data where these dose sizes were utilised (6). against clinical data of TDF once-daily, day 7 profiles for dose size of 300 mg ( Figure   526 2A), 75 mg ( Figure 2B ), 150 mg ( Figure 2C ) and 600 mg ( Figure 2D ) (6). 
